Daihong Liu

This study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to target and clear the virus. About 18 adults who have EBV in their blood despite standard …

This study tests a new treatment called PD-1Ab21-BCMA CAR-T cells for people with multiple myeloma who also have kidney problems. The treatment uses a patient's own immune cells that are modified in a lab to find and attack cancer cells. The goal is to see if this therapy can kee…

This study tests a new treatment called EBV-AST cells for people who have an EBV virus infection after a stem cell transplant. The goal is to find the safest dose and see if it can clear the virus from the blood. About 18 adults aged 18-75 will take part. The treatment uses speci…

This study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common and serious complication after a stem cell transplant. The trial will enroll 168 people who have recen…

This study tests a new treatment for people with B-cell lymphoma or leukemia that has come back or not responded to standard therapy. The treatment uses special particles to deliver mRNA into the body, creating immune cells that target two cancer markers (CD19 and CD20). The goal…

This study tests whether adding the drug ruxolitinib to standard steroids can better control severe graft-versus-host disease (GVHD) after a stem cell transplant. About 54 adults who develop severe GVHD within 100 days of their first transplant will receive the combination. The m…

This study tests whether adding two drugs—chidamide and a PD-1 inhibitor—after CAR-T cell therapy can help people with relapsed or hard-to-treat B-cell lymphoma stay cancer-free longer. About 30 adults with aggressive lymphoma that has come back or not responded to treatment will…

This early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain lymphomas and post-transplant complications. About 18 adults will receive up to three infusions of the t…